NYSE : DLB

Dolby Laboratories, Inc.

$49.15 USD

$0.64 (1.32%)

Volume
616.59K
Average Volume
867.69K
Market Capitalization
$4.7B
P/E Ratio
19.20
Dividend Yield
2.87%
Price Target
$85.00
Year High
$77.00
Year Low
$48.26
Day High
Day Low
Payout Ratio
$0.54
Current Ratio
$2.98
Source Headline
Dolby Laboratories Announces Conference Call and Webcast for Q3 Fiscal 2026 Financial Results

SAN FRANCISCO, July 14, 2026 /PRNewswire/ -- Dolby Laboratories, Inc. (NYSE: DLB), a leader in immersive entertainment experiences, will release financial results for the third quarter (Q3) fiscal year 2026 after the close of regular trading on Thursday, July 30, 2026. Members of Dolby management will lead a conference call open to all interested parties to discuss Q3 fiscal year 2026 financial results for Dolby Laboratories at 2:00 p.m.

prnewswire.com - 2026-07-14 16:15:00

CervoMed Announces New Clinical, Plasma Biomarker and Imaging Data at AAIC 2026 for Neflamapimod in the Treatment of Dementia with Lewy Bodies (DLB)

BOSTON, July 14, 2026 (GLOBE NEWSWIRE) -- CervoMed Announces New Clinical, Plasma Biomarker and Imaging Data at AAIC 2026 for Neflamapimod in the Treatment of Dementia with Lewy Bodies (DLB)

globenewswire.com - 2026-07-14 07:30:00

Cognition Therapeutics: Clearer FDA Path, But Potential Dilution Risks Remain

Cognition Therapeutics is currently prioritizing zervimesine for DLB psychosis. This is after the FDA's feedback gave their planned pivotal program a clearer path. Basically, DLB psychosis has no approved therapy, and zervimesine is a promising oral once-daily drug that already has interesting Phase 2 data. CGTX's SHIMMER trial was a good start, but their next trial must confirm longer-lasting hallucination and delusion benefits.

seekingalpha.com - 2026-06-26 10:07:20

Cognition Therapeutics Aligns on Key Aspects of Pivotal Study for Zervimesine (CT1812) in DLB Psychosis Following Receipt of FDA Meeting Minutes

- Zervimesine Would be the First Long-term, Durable Treatment Option with an Impact on Underlying Disease - - Company Developing NPI as a Measure of DLB Psychosis -

globenewswire.com - 2026-06-24 07:30:00

3 Audio Video Stocks to Watch as Industry Witnesses Headwinds

Amid cautious discretionary spending and macro troubles, investments in cutting-edge solutions are likely to aid Zacks Audio Video Production industry participants like SONY, DLB and SONO.

zacks.com - 2026-06-10 14:00:48

Arista Introduces Next-Generation 1.6Terabit Portfolio for AI Fabrics

Arista Networks (NYSE: ANET), a leader in modern AI fabric networking, today announced the Arista [url="]7060XE7 Series[/url], a new portfolio of 1.6T networki

gurufocus.com - 2026-06-09 10:00:00

Dolby Vision and Dolby Atmos to Power Telemundo's FIFA World Cup 2026™ Coverage on Peacock, a Streaming First

Dolby Vision and Dolby Atmos to Power Telemundo's FIFA World Cup 2026™ Coverage on Peacock, a Streaming First PR Newswire

gurufocus.com - 2026-06-05 11:00:00

Dolby Laboratories, Inc. (DLB) Presents at 2026 Baird Global Consumer, Technology & Services Conference Transcript

Dolby Laboratories, Inc. (DLB) Presents at 2026 Baird Global Consumer, Technology & Services Conference Transcript

seekingalpha.com - 2026-06-04 12:41:58

Dolby Laboratories, Inc. (DLB) Presents at 46th Annual William Blair Growth Stock Conference Transcript

Dolby Laboratories, Inc. (DLB) Presents at 46th Annual William Blair Growth Stock Conference Transcript

seekingalpha.com - 2026-06-03 13:52:02

GE HealthCare Focuses on Expanding Access to Nuclear Medicine Through AI, Radiopharmaceutical and Imaging Innovations

As theranostics adoption acceleratesi and radiopharmaceutical demand grows,ii healthcare systems are under increasing pressure to scale nuclear medicine operat

gurufocus.com - 2026-06-01 09:00:00

Dolby and rednote Bring More Immersive Storytelling to Video Content with Dolby Atmos

/PRNewswire/ -- Dolby Laboratories (NYSE: DLB), a leader in immersive entertainment, and rednote, the leading lifestyle interest community, today announced

prnewswire.com - 2026-05-29 08:30:00

Dolby Recognized as 2025 Supplier of the Year and Overdrive Award Winner by General Motors

SAN FRANCISCO, May 20, 2026 /PRNewswire/ -- Dolby Laboratories  (NYSE: DLB), a leader in immersive entertainment, has earned two of the automotive industry's most prestigious supplier honors from General Motors: the 2025 Supplier of the Year and the Overdrive Award — GM's highest supplier recognition. It marks the first time Dolby has received either distinction, a milestone that reflects the company's leadership in redefining the in-car entertainment experience through innovations like Dolby Atmos.

prnewswire.com - 2026-05-20 09:00:00

Dolby Laboratories to Present at Upcoming Investor Conferences

SAN FRANCISCO, May 19, 2026 /PRNewswire/ -- Dolby Laboratories, Inc. (NYSE:DLB) today announced that management will present at the following investor conferences: Kevin Yeaman, President and CEO, will host a presentation at the William Blair 46th Annual Growth Stock Conference in Chicago, Illinois on Wednesday, June 3, 2026, at 10:00 AM CT (11:00 AM ET). Robert Park, Senior Vice President and Chief Financial Officer, will host a presentation at the Baird Global Consumer, Technology and Services Conference in New York, New York on Thursday, June 4, 2026 at 9:40 AM ET.

prnewswire.com - 2026-05-19 16:15:00

SONY's Q4 Earnings Plunge Y/Y Despite Healthy Revenues, G&NS Weakens

Sony Q4 FY2025 revenues jump 8% to 3,036.4B yen, but GAAP EPS fall to 13.93 yen as gaming and "All Other" weighed on results.

zacks.com - 2026-05-08 11:20:25

Dolby: I Don't Mind Waiting In 2026

Dolby Labs is rated a 'BUY' with a conservative $80/share price target, reflecting 17–25% annualized upside potential through 2028. DLB trades at a rare sub-15x P/E, supported by robust patent-driven recurring revenue, high margins, and a net cash balance exceeding $500M. Despite cyclical end-market exposure and recent earnings volatility, DLB's technology leadership and dominant licensing position underpin long-term revenue security.

seekingalpha.com - 2026-05-03 05:51:07

Why Dolby Labs Stock Crashed Today

Dolby stock is getting static over its Q3 earnings guidance.

fool.com - 2026-05-01 10:00:12

Dolby Q2 Earnings Top Estimates on Licensing Strength, Revenues Up Y/Y

DLB beats Q2 estimates as licensing growth, strong broadcast demand and expanding Dolby Atmos adoption drive revenue and a steady outlook.

zacks.com - 2026-05-01 09:05:32

Dolby Laboratories, Inc. (DLB) Q2 2026 Earnings Call Transcript

Dolby Laboratories, Inc. (DLB) Q2 2026 Earnings Call Transcript

seekingalpha.com - 2026-05-01 01:01:35

Compared to Estimates, Dolby Laboratories (DLB) Q2 Earnings: A Look at Key Metrics

The headline numbers for Dolby Laboratories (DLB) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

zacks.com - 2026-04-30 20:00:21

Dolby Laboratories (DLB) Q2 Earnings and Revenues Top Estimates

Dolby Laboratories (DLB) came out with quarterly earnings of $1.37 per share, beating the Zacks Consensus Estimate of $1.31 per share. This compares to earnings of $1.34 per share a year ago.

zacks.com - 2026-04-30 19:26:38

Dolby Laboratories Reports Second Quarter 2026 Financial Results

SAN FRANCISCO, April 30, 2026 /PRNewswire/ -- Dolby Laboratories, Inc. (NYSE: DLB) today announced the company's financial results for the second quarter of fiscal 2026. "We continue to strengthen our position and create growth opportunities across existing and new business areas," said Kevin Yeaman, President and CEO, Dolby Laboratories.

prnewswire.com - 2026-04-30 16:15:00

Dolby Laboratories (NYSE:DLB) Receives Average Rating of “Moderate Buy” from Analysts

Dolby Laboratories (NYSE: DLB - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the five brokerages that are covering the firm, MarketBeat Ratings reports. Two investment analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average 12 month price objective among

defenseworld.net - 2026-04-19 02:28:58

Get DLB Insider Trade Alerts

DLB Price Target Summary

Last Month

$0.00

0 analysts

Last Quarter

$0.00

0 analysts

Last Year

$79.50

2 analysts

All Time

$90.25

4 analysts

DLB Recent Analyst Grades

Date Analyst Firm Action Previous Grade New Grade
2026-06-15 Barrington Research Maintain Outperform Outperform
2026-06-11 Rosenblatt Maintain Buy Buy
2026-04-27 Barrington Research Maintain Outperform Outperform
2026-01-30 Barrington Research Maintain Outperform Outperform
2026-01-30 Rosenblatt Maintain Buy Buy
2026-01-26 Barrington Research Maintain Outperform Outperform
2026-01-22 Rosenblatt Maintain Buy Buy
2025-11-19 Rosenblatt Maintain Buy Buy
2025-11-19 Barrington Research Maintain Outperform Outperform
2025-09-12 Barrington Research Maintain Outperform Outperform
2025-08-15 Tigress Financial Maintain Buy Buy
2025-08-01 Rosenblatt Maintain Buy Buy
2025-06-13 Rosenblatt Maintain Buy Buy
2025-05-15 Tigress Financial Maintain Buy Buy
2025-05-02 Barrington Research Maintain Outperform Outperform
2025-05-02 Rosenblatt Maintain Buy Buy
2025-02-13 Barrington Research Maintain Outperform Outperform
2025-01-30 Rosenblatt Maintain Buy Buy
2025-01-30 Barrington Research Maintain Outperform Outperform
2025-01-27 Barrington Research Maintain Outperform Outperform
2025-01-23 Rosenblatt Maintain Buy Buy
2024-11-20 Barrington Research Maintain Outperform Outperform
2024-11-20 Rosenblatt Maintain Buy Buy
2024-09-20 Barrington Research Maintain Outperform Outperform
2024-08-09 Barrington Research Maintain Outperform Outperform
2024-06-07 Rosenblatt Maintain Buy Buy
2024-06-03 Barrington Research Upgrade Market Perform Outperform
2024-05-03 Rosenblatt Maintain Buy Buy
2024-04-29 Rosenblatt Maintain Buy Buy
2024-01-31 Rosenblatt Maintain Buy Buy
2023-12-11 Rosenblatt Maintain Buy Buy
2023-11-17 Rosenblatt Maintain Buy Buy
2023-08-04 Rosenblatt Maintain Buy Buy
2023-07-28 Rosenblatt Maintain Buy Buy
2023-06-01 Rosenblatt Maintain Buy Buy
2023-04-26 Rosenblatt Maintain Buy Buy
2023-04-14 Tigress Financial Maintain Buy Buy
2023-02-03 Rosenblatt Maintain Buy Buy
2022-11-18 Barrington Research Downgrade Outperform Market Perform
2022-11-07 Rosenblatt Maintain Buy Buy
2022-10-14 Tigress Financial Maintain Buy Buy
2022-08-26 Rosenblatt Maintain Buy Buy
2022-05-24 Rosenblatt Maintain Buy Buy
2021-08-02 Barrington Research Upgrade Market Perform Outperform
2021-01-29 B. Riley FBR Maintain Neutral Neutral
2021-01-29 B. Riley Securities Maintain Neutral Neutral
2021-01-28 B. Riley FBR Maintain Neutral Neutral
2020-06-24 B. Riley Securities Downgrade Buy Neutral
2020-06-24 B. Riley FBR Downgrade Buy Neutral
2020-05-05 B. Riley FBR Maintain Buy Buy
2020-05-05 JP Morgan Maintain Overweight Overweight
2020-05-05 B. Riley Securities Maintain Buy Buy
2020-04-15 B. Riley Securities Maintain Buy Buy
2020-04-15 B. Riley FBR Maintain Buy Buy
2020-03-24 B. Riley Upgrade Neutral Buy
2020-03-24 B. Riley Securities Upgrade Neutral Buy
2020-03-24 B. Riley FBR Upgrade Neutral Buy
2020-03-18 B. Riley Securities Maintain Neutral Neutral
2020-03-18 B. Riley FBR Maintain Neutral Neutral
2020-03-13 JP Morgan Upgrade Neutral Overweight
2020-01-10 B. Riley FBR Downgrade Buy Neutral
2020-01-10 B. Riley Securities Downgrade Buy Neutral
2019-08-02 B. Riley Securities Maintain Neutral Neutral
2019-08-02 B. Riley FBR Maintain Neutral Neutral
2018-10-25 B. Riley Securities Maintain Neutral Neutral
2018-10-25 B. Riley FBR Maintain Neutral Neutral
2018-10-22 RF Lafferty Maintain Buy Buy
2018-05-05 B. Riley FBR Maintain Neutral Neutral
2018-05-05 B. Riley FBR Downgrade Buy Neutral
2018-05-05 B. Riley FBR Upgrade Neutral Buy
2018-01-25 JP Morgan Maintain Neutral Neutral
2018-01-16 B. Riley Securities Downgrade Buy Neutral
2018-01-16 B. Riley FBR Downgrade Buy Neutral
2017-10-19 B. Riley Securities Maintain Buy Buy
2017-10-19 B. Riley FBR Maintain Buy Buy
2017-07-17 B. Riley Securities Upgrade Neutral Buy
2017-07-17 B. Riley FBR Upgrade Neutral Buy
2016-10-27 Barrington Research Upgrade Market Perform Outperform
2016-04-08 JP Morgan Downgrade Overweight Neutral
2016-01-28 Dougherty Upgrade Neutral Buy
2016-01-28 Dougherty & Co. Upgrade Neutral Buy
2016-01-28 JP Morgan Maintain Overweight Overweight
2015-10-22 B. Riley FBR Maintain Neutral Neutral
2015-10-22 B. Riley Securities Maintain Neutral Neutral
2015-04-22 JP Morgan Upgrade Neutral Overweight
2014-10-13 JP Morgan Maintain Neutral Neutral
2014-07-25 JP Morgan Maintain Underweight Underweight
2014-07-01 B. Riley FBR Maintain Neutral Neutral
2014-04-30 JP Morgan Maintain Underweight Underweight
2014-01-23 S&P Capital IQ Downgrade Hold Sell
2013-07-26 Dougherty & Co. Downgrade Buy Neutral
2013-07-26 Dougherty Downgrade Buy Neutral
2013-06-11 Avondale Partners Downgrade Market Outperform Market Perform
2013-04-16 Tigress Financial Downgrade Strong Buy Buy
2012-12-19 Goldman Sachs Maintain Sell Sell
2012-11-13 Barrington Research Downgrade Outperform Market Perform
2012-11-05 JMP Securities Downgrade Market Perform Market Underperform
2012-09-27 PiperJaffray Maintain Neutral Neutral
2012-09-27 Piper Sandler Maintain Neutral Neutral
2012-08-17 Barrington Research Maintain Outperform Outperform
2012-07-18 JP Morgan Downgrade Neutral Underweight
2012-06-28 Goldman Sachs Maintain Sell Sell
2012-05-10 JP Morgan Downgrade Overweight Neutral
2012-05-08 Canaccord Genuity Maintain Hold Hold
2012-05-04 Dougherty & Co. Maintain Buy Buy
2012-05-04 Dougherty Maintain Buy Buy